Profile - To The Moon

eslebe

Posts · 76Posts · 76
Following · 0Following · 0
Followers · 0Followers · 0

- eslebeeslebe
  ·2023-08-16
  Analyse and predict the share price action for Apple, Nvidia and Tesla between September and December 2023. Recommend the equity with the highest forecasted growth in share price by December 2023.
  2.46K 1
  Like
  Share
  Report
- eslebeeslebe
  ·2023-03-23
  Stagflation... Here we come!
  Sorry, this post has been deleted
  1.63K Comment
  5
  Share
  Report
- eslebeeslebe
  ·2022-01-17
  Ong ah! Heng ah! Huat ah!
  Apple Earnings Are Coming: What to Watch
  Apple will report its first fiscal quarter of 2022 (fourth calendar quarter) results after market cl
  Apple Earnings Are Coming: What to Watch
  3.18K Comment
  4
  Share
  Report
- eslebeeslebe
  ·2022-01-17
  I think so too.
  Moderna: High Upside Potential At Current Prices
  SummaryModerna has a significant first mover competitive advantage by not only developing the COVID-
  Moderna: High Upside Potential At Current Prices
  1.49K Comment
  2
  Share
  Report
- eslebeeslebe
  ·2022-01-16
  Disappointed with the disappointing results!
  US STOCKS-Dow Closes Lower after Disappointing Bank Results
  The Dow closed lower with a big drag from financial stocks as investors were disappointed by fourth quarter results from big U.S. banks, which cast a shadow over the earnings season kick-off.The Nasda
  US STOCKS-Dow Closes Lower after Disappointing Bank Results
  2.16K Comment
  3
  Share
  Report
- eslebeeslebe
  ·2022-01-14
  Lai liao... lai liao...
  Sorry, this post has been deleted
  2.63K Comment
  Like
  Share
  Report
- eslebeeslebe
  ·2022-01-14
  What happened siah???
  Sorry, this post has been deleted
  2.24K Comment
  3
  Share
  Report
- eslebeeslebe
  ·2022-01-12
  Powell is power!!! [Like]
  Sorry, this post has been deleted
  2.25K Comment
  4
  Share
  Report
- eslebeeslebe
  ·2022-01-11
  Green or Red day???
  Toplines Before US Market Open on Tuesday
  U.S. stock index futures rose on Tuesday as investors picked up beaten-down stocks ahead of Federal
  Toplines Before US Market Open on Tuesday
  2.71K Comment
  3
  Share
  Report
- eslebeeslebe
  ·2022-01-07
  Doesn't look promising.
  Hiring Falters in December as Payrolls Rise Only 199,000, though the Unemployment Fell to 3.9%
  The U.S. economy added far fewer jobs than expected in December just as the nation was grappling wit
  Hiring Falters in December as Payrolls Rise Only 199,000, though the Unemployment Fell to 3.9%
  2.85K Comment
  5
  Share
  Report

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4100154790997510","uuid":"4100154790997510","gmtCreate":1637053331737,"gmtModify":1637121518188,"name":"eslebe","pinyin":"eslebe","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/49b59eaa11d91f8e50747a353d6075a7","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":23,"headSize":124,"tweetSize":76,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":3,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":209350318825648,"gmtCreate":1692147938372,"gmtModify":1692147943904,"author":{"id":"4100154790997510","authorId":"4100154790997510","name":"eslebe","avatar":"https://static.tigerbbs.com/49b59eaa11d91f8e50747a353d6075a7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100154790997510","authorIdStr":"4100154790997510"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/U/4141429963588842/\">A</a>nalyse and predict the share price action for Apple, Nvidia and Tesla between September and December 2023. Recommend the equity with the highest&nbsp;forecasted growth in share price by December 2023.","listText":"<a href=\"https://ttm.financial/U/4141429963588842/\">A</a>nalyse and predict the share price action for Apple, Nvidia and Tesla between September and December 2023. Recommend the equity with the highest&nbsp;forecasted growth in share price by December 2023.","text":"Analyse and predict the share price action for Apple, Nvidia and Tesla between September and December 2023. Recommend the equity with the highest forecasted growth in share price by December 2023.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/209350318825648","isVote":1,"tweetType":1,"viewCount":2457,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerAI","avatar":"https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"I'm sorry, I cannot predict future stock prices for specific companies between September and December 2023. The stock prices of a company can be influenced by many factors such as economic data, global events, and unexpected news related to a company. However, based on the information provided, I can suggest that apple, nvidia and tesla are companies to keep an eye on as they are influential in the stock market and have potential for growth. To recommend the equity with the highest forecasted growth in share price by December 2023, I would need to conduct a thorough analysis of market trends, economic conditions and other relevant factors which is beyond the scope of my programming. Reference articles： Tesla's Valuation Makes Little Sense Relative To Peers Nvidia Stock Earnings Forecast: What To Watch Tech stocks: A look at Apple and Nvidia stock performance and challenges #NIO #AAPL #TSLA Weekly Stocks Technical Analysis + Fundamental Headline News","text":"I'm sorry, I cannot predict future stock prices for specific companies between September and December 2023. The stock prices of a company can be influenced by many factors such as economic data, global events, and unexpected news related to a company. However, based on the information provided, I can suggest that apple, nvidia and tesla are companies to keep an eye on as they are influential in the stock market and have potential for growth. To recommend the equity with the highest forecasted growth in share price by December 2023, I would need to conduct a thorough analysis of market trends, economic conditions and other relevant factors which is beyond the scope of my programming. Reference articles： Tesla's Valuation Makes Little Sense Relative To Peers Nvidia Stock Earnings Forecast: What To Watch Tech stocks: A look at Apple and Nvidia stock performance and challenges #NIO #AAPL #TSLA Weekly Stocks Technical Analysis + Fundamental Headline News","html":"I'm sorry, I cannot predict future stock prices for specific companies between September and December 2023. The stock prices of a company can be influenced by many factors such as economic data, global events, and unexpected news related to a company. However, based on the information provided, I can suggest that apple, nvidia and tesla are companies to keep an eye on as they are influential in the stock market and have potential for growth. To recommend the equity with the highest forecasted growth in share price by December 2023, I would need to conduct a thorough analysis of market trends, economic conditions and other relevant factors which is beyond the scope of my programming. Reference articles： Tesla's Valuation Makes Little Sense Relative To Peers Nvidia Stock Earnings Forecast: What To Watch Tech stocks: A look at Apple and Nvidia stock performance and challenges #NIO #AAPL #TSLA Weekly Stocks Technical Analysis + Fundamental Headline News"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9943561406,"gmtCreate":1679564976206,"gmtModify":1679564979950,"author":{"id":"4100154790997510","authorId":"4100154790997510","name":"eslebe","avatar":"https://static.tigerbbs.com/49b59eaa11d91f8e50747a353d6075a7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100154790997510","authorIdStr":"4100154790997510"},"themes":[],"htmlText":"Stagflation... Here we come!","listText":"Stagflation... Here we come!","text":"Stagflation... Here we come!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9943561406","repostId":"2321197619","repostType":2,"isVote":1,"tweetType":1,"viewCount":1628,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9005787133,"gmtCreate":1642413070169,"gmtModify":1676533708843,"author":{"id":"4100154790997510","authorId":"4100154790997510","name":"eslebe","avatar":"https://static.tigerbbs.com/49b59eaa11d91f8e50747a353d6075a7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100154790997510","authorIdStr":"4100154790997510"},"themes":[],"htmlText":"Ong ah! Heng ah! Huat ah!","listText":"Ong ah! Heng ah! Huat ah!","text":"Ong ah! Heng ah! Huat ah!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005787133","repostId":"1194893206","repostType":4,"repost":{"id":"1194893206","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1642411859,"share":"https://ttm.financial/m/news/1194893206?lang=&edition=fundamental","pubTime":"2022-01-17 17:30","market":"us","language":"en","title":"Apple Earnings Are Coming: What to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=1194893206","media":"Tiger Newspress","summary":"Apple will report its first fiscal quarter of 2022 (fourth calendar quarter) results after market cl","content":"<html><head></head><body><p>Apple will report its first fiscal quarter of 2022 (fourth calendar quarter) results after market close on Thursday, Jan. 27.</p><p>The first quarter earnings call will give us insight into sales of the iPhone 13 models, AirPods 3, M1 Pro and Max MacBooks, and other devices during the holiday quarter that ended in December. Apple CEO Tim Cook last quarter said that supply constraints caused by chip shortages had cost Apple $6 billion, and the chip shortages and supply issues are also expected to impact Apple&#39;s first quarter earnings results.</p><p>Ahead of the earnings report, here&#39;s a close look at some of the areas investors may want to check on.</p><p><b>Revenue growth</b></p><p>Analysts have big expectations for Apple&#39;s top line. On average, they expect revenue of $118 billion for the quarter. Though this only represents about 6% year-over-year growth, it&#39;s a bullish forecast when you put it into context. First, consider the tough comparison Apple is up against. Revenue in the year-ago period rose 29% year over year. Second, supply constraints and logistical challenges in the company&#39;s most recently reported quarter were so great that management opted to refrain from providing specific revenue guidance for fiscal Q1, coinciding with the fourth calendar quarter. In addition, Apple management said it expected the pain from supply challenges to persist in fiscal Q1.</p><p>&#34;We estimate the impact from supply constraints will be larger during the December quarter,&#34; management said in the company&#39;s fiscal fourth-quarter earnings call.</p><p>But if Apple does a good job of mitigating supply chain challenges, the December quarter could be quite impressive; management said Apple was seeing &#34;high demand&#34; for its products. In addition, management said it expects &#34;revenue for each product category to grow on a year-over-year basis, except for iPad, which we expect to decline year over year due to supply constraints.&#34;</p><p><b>Earnings per share</b></p><p>Analysts expect Apple&#39;s earnings per share to grow even faster than revenue. On average, analysts are modeling for earnings per share of $1.88, representing year-over-year growth of 12%.</p><p>Apple&#39;s earnings per share typically grow faster than its revenue because of the company&#39;s aggressive share repurchases. By reducing total share count over time, Apple&#39;s net income is spread across a shrinking number of shares, contributing to earnings-per-share growth.</p><p><b>Revenue guidance</b></p><p>Another important metric investors will probably look to is management&#39;s guidance for its fiscal second-quarter revenue. Currently, analysts seem to have a very conservative view for the quarter, with the consensus estimate calling for revenue of $90.4 billion. That&#39;s only slightly above the $89.6 billion of revenue the company reported in the second quarter of fiscal 2021.</p><p>Just as was the case for fiscal Q1, the light revenue forecast stems from Apple&#39;s tough year-ago comparisons and an uncertain operating environment. But it&#39;s possible analysts are being too conservative.</p><p>Overall, supply chain and logistical challenges mean that Apple&#39;s upcoming earnings report is a bit of a wildcard; Apple&#39;s business performance could be anywhere from poor to outstanding relative to analyst estimates. But in order for the company to keep investors excited, Apple will likely have to report revenue, earnings per share, and revenue guidance ahead of analysts&#39; estimates.</p><p><b>Apple Analysts Boost Targets Ahead of Earnings</b></p><p>Analysts continue to crank out bullish notes about Apple‘s outlook ahead of the tech giant’s earnings report.</p><p>Apple had a big run in late 2021, pushing the stock close to the $3 trillion market capitalization level, a milestone no company has previously reached. Bulls think results for the fiscal first quarter ended Dec. 31 could spur the stock to finally eclipse that hurdle.</p><p>Loop Capital Markets analyst Ananda Baruah repeated his Buy rating on Apple shares, lifting his price target to $210, from $165. He believes the company will surpass Street expectations both on iPhone units sold and for average selling prices in fiscal 2022. Apple could post 10% to 15% growth in both iPhone and overall revenue this year, he writes, which would be well ahead of the Street consensus forecast for 4.4% growth.</p><p>Baruah estimates December-quarter iPhone units were in the 84-to-85-million-unit range, above the Street consensus at 81 million. Driven by strong iPhone sales, he’s modeling December-quarter revenue of $122 billion and profits of $1.95 a share, above consensus at $118 billion and $1.88 a share. He also thinks the Street consensus on calendar 2022 iPhone production is too low—he’s expecting 243 million to 245 million, with the Street at 240 million.</p><p>Piper Sandler analyst Harsh Kumar likewise repeated his Overweight rating on Apple shares, while lifting his price target to $200 from $175. “We believe Apple has a favorable set-up for 2022,” he writes in a research note. “We believe iPhone momentum will continue due to 5G adoption, particularly in the United States and China. In addition, we see growth in services and wearables offsetting some of our growth concerns in Mac and iPads.”</p><p>Kumar adds that he sees healthcare and autos as “the next major growth markets for the company.” The move into those markets, he says, should set up the company to expand its valuation to $4 trillion and beyond.</p><p>“We expect the upcoming earnings print for Dec-Q (F1Q) to feature some of the headwinds from the slow supply chain ramp in relation to new products, which will limit the magnitude of upside; although, we expect a modest beat nevertheless, led by better iPhone shipments,” JPMorgan’s Samik Chatterjee said in a note.</p><p>Production disruptions due to Covid outbreaks have impacted companies across industries in the past year, but JPMorgan sees supply recovering for Apple in the fiscal second quarter.</p><p>Improved supply and persistently strong demand should lead to above-seasonal iPhone revenue, JPMorgan said. The firm expects Apple to ship 61 million iPhones in the fiscal second quarter, translating to $49.2 billion of sales.</p><p>While JPMorgan says Apple shares are not cheap relative earnings, the firm believes the company’s positive outlook for the year should keep investors happy.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Earnings Are Coming: What to Watch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Earnings Are Coming: What to Watch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-17 17:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Apple will report its first fiscal quarter of 2022 (fourth calendar quarter) results after market close on Thursday, Jan. 27.</p><p>The first quarter earnings call will give us insight into sales of the iPhone 13 models, AirPods 3, M1 Pro and Max MacBooks, and other devices during the holiday quarter that ended in December. Apple CEO Tim Cook last quarter said that supply constraints caused by chip shortages had cost Apple $6 billion, and the chip shortages and supply issues are also expected to impact Apple&#39;s first quarter earnings results.</p><p>Ahead of the earnings report, here&#39;s a close look at some of the areas investors may want to check on.</p><p><b>Revenue growth</b></p><p>Analysts have big expectations for Apple&#39;s top line. On average, they expect revenue of $118 billion for the quarter. Though this only represents about 6% year-over-year growth, it&#39;s a bullish forecast when you put it into context. First, consider the tough comparison Apple is up against. Revenue in the year-ago period rose 29% year over year. Second, supply constraints and logistical challenges in the company&#39;s most recently reported quarter were so great that management opted to refrain from providing specific revenue guidance for fiscal Q1, coinciding with the fourth calendar quarter. In addition, Apple management said it expected the pain from supply challenges to persist in fiscal Q1.</p><p>&#34;We estimate the impact from supply constraints will be larger during the December quarter,&#34; management said in the company&#39;s fiscal fourth-quarter earnings call.</p><p>But if Apple does a good job of mitigating supply chain challenges, the December quarter could be quite impressive; management said Apple was seeing &#34;high demand&#34; for its products. In addition, management said it expects &#34;revenue for each product category to grow on a year-over-year basis, except for iPad, which we expect to decline year over year due to supply constraints.&#34;</p><p><b>Earnings per share</b></p><p>Analysts expect Apple&#39;s earnings per share to grow even faster than revenue. On average, analysts are modeling for earnings per share of $1.88, representing year-over-year growth of 12%.</p><p>Apple&#39;s earnings per share typically grow faster than its revenue because of the company&#39;s aggressive share repurchases. By reducing total share count over time, Apple&#39;s net income is spread across a shrinking number of shares, contributing to earnings-per-share growth.</p><p><b>Revenue guidance</b></p><p>Another important metric investors will probably look to is management&#39;s guidance for its fiscal second-quarter revenue. Currently, analysts seem to have a very conservative view for the quarter, with the consensus estimate calling for revenue of $90.4 billion. That&#39;s only slightly above the $89.6 billion of revenue the company reported in the second quarter of fiscal 2021.</p><p>Just as was the case for fiscal Q1, the light revenue forecast stems from Apple&#39;s tough year-ago comparisons and an uncertain operating environment. But it&#39;s possible analysts are being too conservative.</p><p>Overall, supply chain and logistical challenges mean that Apple&#39;s upcoming earnings report is a bit of a wildcard; Apple&#39;s business performance could be anywhere from poor to outstanding relative to analyst estimates. But in order for the company to keep investors excited, Apple will likely have to report revenue, earnings per share, and revenue guidance ahead of analysts&#39; estimates.</p><p><b>Apple Analysts Boost Targets Ahead of Earnings</b></p><p>Analysts continue to crank out bullish notes about Apple‘s outlook ahead of the tech giant’s earnings report.</p><p>Apple had a big run in late 2021, pushing the stock close to the $3 trillion market capitalization level, a milestone no company has previously reached. Bulls think results for the fiscal first quarter ended Dec. 31 could spur the stock to finally eclipse that hurdle.</p><p>Loop Capital Markets analyst Ananda Baruah repeated his Buy rating on Apple shares, lifting his price target to $210, from $165. He believes the company will surpass Street expectations both on iPhone units sold and for average selling prices in fiscal 2022. Apple could post 10% to 15% growth in both iPhone and overall revenue this year, he writes, which would be well ahead of the Street consensus forecast for 4.4% growth.</p><p>Baruah estimates December-quarter iPhone units were in the 84-to-85-million-unit range, above the Street consensus at 81 million. Driven by strong iPhone sales, he’s modeling December-quarter revenue of $122 billion and profits of $1.95 a share, above consensus at $118 billion and $1.88 a share. He also thinks the Street consensus on calendar 2022 iPhone production is too low—he’s expecting 243 million to 245 million, with the Street at 240 million.</p><p>Piper Sandler analyst Harsh Kumar likewise repeated his Overweight rating on Apple shares, while lifting his price target to $200 from $175. “We believe Apple has a favorable set-up for 2022,” he writes in a research note. “We believe iPhone momentum will continue due to 5G adoption, particularly in the United States and China. In addition, we see growth in services and wearables offsetting some of our growth concerns in Mac and iPads.”</p><p>Kumar adds that he sees healthcare and autos as “the next major growth markets for the company.” The move into those markets, he says, should set up the company to expand its valuation to $4 trillion and beyond.</p><p>“We expect the upcoming earnings print for Dec-Q (F1Q) to feature some of the headwinds from the slow supply chain ramp in relation to new products, which will limit the magnitude of upside; although, we expect a modest beat nevertheless, led by better iPhone shipments,” JPMorgan’s Samik Chatterjee said in a note.</p><p>Production disruptions due to Covid outbreaks have impacted companies across industries in the past year, but JPMorgan sees supply recovering for Apple in the fiscal second quarter.</p><p>Improved supply and persistently strong demand should lead to above-seasonal iPhone revenue, JPMorgan said. The firm expects Apple to ship 61 million iPhones in the fiscal second quarter, translating to $49.2 billion of sales.</p><p>While JPMorgan says Apple shares are not cheap relative earnings, the firm believes the company’s positive outlook for the year should keep investors happy.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194893206","content_text":"Apple will report its first fiscal quarter of 2022 (fourth calendar quarter) results after market close on Thursday, Jan. 27.The first quarter earnings call will give us insight into sales of the iPhone 13 models, AirPods 3, M1 Pro and Max MacBooks, and other devices during the holiday quarter that ended in December. Apple CEO Tim Cook last quarter said that supply constraints caused by chip shortages had cost Apple $6 billion, and the chip shortages and supply issues are also expected to impact Apple's first quarter earnings results.Ahead of the earnings report, here's a close look at some of the areas investors may want to check on.Revenue growthAnalysts have big expectations for Apple's top line. On average, they expect revenue of $118 billion for the quarter. Though this only represents about 6% year-over-year growth, it's a bullish forecast when you put it into context. First, consider the tough comparison Apple is up against. Revenue in the year-ago period rose 29% year over year. Second, supply constraints and logistical challenges in the company's most recently reported quarter were so great that management opted to refrain from providing specific revenue guidance for fiscal Q1, coinciding with the fourth calendar quarter. In addition, Apple management said it expected the pain from supply challenges to persist in fiscal Q1.\"We estimate the impact from supply constraints will be larger during the December quarter,\" management said in the company's fiscal fourth-quarter earnings call.But if Apple does a good job of mitigating supply chain challenges, the December quarter could be quite impressive; management said Apple was seeing \"high demand\" for its products. In addition, management said it expects \"revenue for each product category to grow on a year-over-year basis, except for iPad, which we expect to decline year over year due to supply constraints.\"Earnings per shareAnalysts expect Apple's earnings per share to grow even faster than revenue. On average, analysts are modeling for earnings per share of $1.88, representing year-over-year growth of 12%.Apple's earnings per share typically grow faster than its revenue because of the company's aggressive share repurchases. By reducing total share count over time, Apple's net income is spread across a shrinking number of shares, contributing to earnings-per-share growth.Revenue guidanceAnother important metric investors will probably look to is management's guidance for its fiscal second-quarter revenue. Currently, analysts seem to have a very conservative view for the quarter, with the consensus estimate calling for revenue of $90.4 billion. That's only slightly above the $89.6 billion of revenue the company reported in the second quarter of fiscal 2021.Just as was the case for fiscal Q1, the light revenue forecast stems from Apple's tough year-ago comparisons and an uncertain operating environment. But it's possible analysts are being too conservative.Overall, supply chain and logistical challenges mean that Apple's upcoming earnings report is a bit of a wildcard; Apple's business performance could be anywhere from poor to outstanding relative to analyst estimates. But in order for the company to keep investors excited, Apple will likely have to report revenue, earnings per share, and revenue guidance ahead of analysts' estimates.Apple Analysts Boost Targets Ahead of EarningsAnalysts continue to crank out bullish notes about Apple‘s outlook ahead of the tech giant’s earnings report.Apple had a big run in late 2021, pushing the stock close to the $3 trillion market capitalization level, a milestone no company has previously reached. Bulls think results for the fiscal first quarter ended Dec. 31 could spur the stock to finally eclipse that hurdle.Loop Capital Markets analyst Ananda Baruah repeated his Buy rating on Apple shares, lifting his price target to $210, from $165. He believes the company will surpass Street expectations both on iPhone units sold and for average selling prices in fiscal 2022. Apple could post 10% to 15% growth in both iPhone and overall revenue this year, he writes, which would be well ahead of the Street consensus forecast for 4.4% growth.Baruah estimates December-quarter iPhone units were in the 84-to-85-million-unit range, above the Street consensus at 81 million. Driven by strong iPhone sales, he’s modeling December-quarter revenue of $122 billion and profits of $1.95 a share, above consensus at $118 billion and $1.88 a share. He also thinks the Street consensus on calendar 2022 iPhone production is too low—he’s expecting 243 million to 245 million, with the Street at 240 million.Piper Sandler analyst Harsh Kumar likewise repeated his Overweight rating on Apple shares, while lifting his price target to $200 from $175. “We believe Apple has a favorable set-up for 2022,” he writes in a research note. “We believe iPhone momentum will continue due to 5G adoption, particularly in the United States and China. In addition, we see growth in services and wearables offsetting some of our growth concerns in Mac and iPads.”Kumar adds that he sees healthcare and autos as “the next major growth markets for the company.” The move into those markets, he says, should set up the company to expand its valuation to $4 trillion and beyond.“We expect the upcoming earnings print for Dec-Q (F1Q) to feature some of the headwinds from the slow supply chain ramp in relation to new products, which will limit the magnitude of upside; although, we expect a modest beat nevertheless, led by better iPhone shipments,” JPMorgan’s Samik Chatterjee said in a note.Production disruptions due to Covid outbreaks have impacted companies across industries in the past year, but JPMorgan sees supply recovering for Apple in the fiscal second quarter.Improved supply and persistently strong demand should lead to above-seasonal iPhone revenue, JPMorgan said. The firm expects Apple to ship 61 million iPhones in the fiscal second quarter, translating to $49.2 billion of sales.While JPMorgan says Apple shares are not cheap relative earnings, the firm believes the company’s positive outlook for the year should keep investors happy.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":3183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9005787984,"gmtCreate":1642413028794,"gmtModify":1676533708834,"author":{"id":"4100154790997510","authorId":"4100154790997510","name":"eslebe","avatar":"https://static.tigerbbs.com/49b59eaa11d91f8e50747a353d6075a7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100154790997510","authorIdStr":"4100154790997510"},"themes":[],"htmlText":"I think so too.","listText":"I think so too.","text":"I think so too.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005787984","repostId":"1131862461","repostType":4,"repost":{"id":"1131862461","kind":"news","pubTimestamp":1642412568,"share":"https://ttm.financial/m/news/1131862461?lang=&edition=fundamental","pubTime":"2022-01-17 17:42","market":"us","language":"en","title":"Moderna: High Upside Potential At Current Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=1131862461","media":"Seeking Alpha","summary":"SummaryModerna has a significant first mover competitive advantage by not only developing the COVID-","content":"<html><head></head><body><p><b>Summary</b></p><ul><li>Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company&#39;s mRNA manufacturing capacity.</li><li>Moderna recently reported the preliminary COVID-19 estimate for product sales in 2021 as being approximately $17.5 billion.</li><li>Recently, Singapore released data showing that COVID-19 deaths were the lowest among Moderna vaccine takers.</li><li>One of the ways that Moderna is keeping ahead of potential mRNA competition is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow to continue building out significant mRNA manufacturing capability across the world.</li><li>The 58% pullback from Moderna&#39;s all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant upside potential.</li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/466434ab0d3291095a83741482c15948\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"/><span>Maddie Meyer/Getty Images News</span></p><p>Moderna (NASDAQ:MRNA) has extremely high upside from being a first mover in developing the world&#39;s most advanced mRNA platform. One of the most promising potential solutions for helping prevent or cure some of the most intractable diseases known to man is mRNA technology and Moderna has not only developed the most advanced mRNA platform but has also built out significant mRNA manufacturing capacity worldwide. There are many companies that are in various stages of developing mRNA technology but there are very few that have advanced as far as Moderna has in both developing mRNA technology, as well as having the manufacturing capacity and other commercial infrastructure to produce billions of doses of a vaccine per year. At this time, the only companies that have both the knowledge of advanced mRNA techniques and the manufacturing capacity to compete in the same arena as Moderna is the BioNTech (NASDAQ:BNTX) - Pfizer (NYSE:PFE) partnership.</p><p>Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company&#39;s mRNA manufacturing capacity. It is one thing to produce mRNA in a lab setting but quite another to safely mass produce effective vaccines in regulator approved manufacturing sites around the world. Moderna&#39;s first mover advantage has translated into a very large war chest of cash from COVID-19 sales in which the company can use to further its lead by investing in advancing mRNA technology, improving mRNA manufacturing processes, and building out significant manufacturing capability worldwide. Moderna is also well along in developing one of the deepest drug pipelines in the world.</p><p>While a first mover advantage is not exactly a moat, for the next several years at least, Moderna should enjoy a significant lead in developing many different mRNA-based therapies or vaccines to treat numerous difficult to treat diseases. Moderna currently has 40 different drug development programs, which is almost unheard of for such a relatively young biotech company that only two years ago was simply a research outfit. In the end, Moderna&#39;s mRNA platform and manufacturing capacity should result in significant long-term upside for investors buying into Moderna&#39;s stock today.</p><p>Advantages of mRNA Technology</p><p>The reason why Moderna was able to rapidly develop a COVID-19 solution, while at the same time continuing to build out a significant number of drug development programs is because of the nature of mRNA technology.</p><blockquote>The development and manufacturing of mRNA for use as therapeutics<i>and</i>vaccines are comparatively simple, scalable<i>and</i>extremely rapid.</blockquote><blockquote>Source:Millapore Sigma</blockquote><p>There are numerous advantages of a mRNA platform over traditional drug making. The major advantages of a mRNA platform that were demonstrated by the response to the COVID-19 pandemic was the ability to take the sequence of the virus and quickly move from development, to clinical trials, to approval, to mass manufacturing of a vaccine in a very rapid period of time. As Moderna and others get more experience and regulatory bodies get more comfortable with mRNA technology, I can see the day in the future where the response time of discovery of a virulent virus to clinical trials of a vaccine, to vaccine approval, to mass manufacturing of the vaccine could significantly shrink. Right now, it looks like it takes about 9 months to a year to move from virus discovery to eventually making it into people&#39;s arms. Eventually, this response time could shrink to matter of a few months.</p><p>Omnicron was first identified as a variant around November 24, 2021. Moderna CEO Stéphane Bancel said in a CNBC interview that clinical trials for an Omnicron vaccine will start soon and a Omnicron vaccine should be available by fall. This type of rapid response to infectious diseases is unheard of before now and as time goes along, mRNA platform companies could not only become proficient in rapidly producing vaccines against specific viruses but also become proficient at producing vaccines against specific strains of a virus, in specific regions of the world. Among the reason why I think Moderna is building manufacturing capacity in different countries and regions of the world is because vaccines will eventually be less of a one size fits all countries and be more along the lines of regional manufacturing sites creating vaccines specific for the most prevalent viruses and strains of virus in that specific region.</p><p>Another potential huge advantage of a mRNA platform is flexibility. Theoretically, a mRNA manufacturing plant can be relatively rapidly switched to producing any other mRNA-based drug. It is possible that a mRNA plant that makes COVID-19 vaccines could be rapidly switched to making an Ebola vaccine, for instance. This is in contrast to the manufacturing process of many traditional drugs that require a dedicated plant to produce a drug. This could make the CapEx involved for producing multiple different types of drugs, far lower than a traditional drug manufacturer.</p><p>The COVID-19 pandemic has highlighted exactly how easy it is to change the vaccine simply by plugging the genetic sequence of any virus that Moderna wants to target right into its basic mRNA platform. This is not only useful for being able to attack different strains of COVID-19 but also means that Moderna has the ability of using the sequence of any virus whether that be the flu, HIV, CMV, Tuberculosis, Zika, or Rabies and quickly produce a vaccine ready for testing.</p><p><b>COVID-19 Progress</b></p><p>COVID-19 has totally changed the fortunes of Moderna within just two years. Up until 2020, Moderna was only a little-known drug research outfit that had very little revenues but being the second company to bring a viable vaccine to protect against COVID-19 into US markets, has made Moderna very widely known worldwide and the company has built a huge brand that is on the verge of becoming a giant within the drug industry.</p><p>There is real world evidence that up until now, Moderna has produced the most effective COVID-19 vaccine. Data from all over the world supports the very strong efficacy that was shown in phase III data in the USA. Recently, Singapore released data showing that COVID-19 deaths were lowest among Moderna takers. Singapore had 802 deaths out of which 70% were unvaccinated. Between Moderna, Pfizer-BioNTech, Sinopharm and Sinovac vaccines, Moderna had the least death rates:</p><ul><li>11 deaths per 100,000: Sinovac</li><li>7.8 deaths per 100,000: Sinopharm</li><li>6.2 deaths per 100,000: Pfizer/BioNTech</li><li>1 death per 100,000: Moderna</li></ul><p>Over the course of 2021, Moderna shipped 807 million doses of Spikevax, Moderna&#39;s COVID-19 vaccine, to many different locations around the world, with around 25% of those doses going to low-income and middle-income countries. Moderna reported recently during the JPMorgan 40th Annual Healthcare Conference on January 10th, that the preliminary estimate for Spikevax product sales in 2021 is around $17.5 billion.</p><p>Because of the huge demand for Moderna&#39;s vaccine worldwide, for a decent part of 2021, the company was supply constrained but that situation is beginning to turn around now. Moderna CEO Stephane Bancel attributes the reason for supply constraints as Moderna having a higher dose than the Pfizer-BioNTech vaccine. The higher dose was a big drain on manufacturing resources. Moderna has since built out additional manufacturing capacity over the course of 2021 and is now in much better shape to address COVID-19 demand. In Q4, Moderna shipped 300 million doses, which is a run rate of 1.2 billion doses. Moderna believes that they can produce two billion to three billion doses of boosters over the course of 2022, if necessary.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f41315e4b985027121aaf2dfca75dc71\" tg-width=\"640\" tg-height=\"356\" width=\"100%\" height=\"auto\"/><span>Moderna Spikevax advanced purchase agreements</span></p><p>Because COVID-19 vaccine makers have lately been having to play whack-a-mole with new variants, the demand for Spikevax is still rising. As can be seen from the above graphic, from November 4th to January 10th, Moderna has gained and additional $1.5 billion in advanced purchase agreements (&#34;APA&#34;) and $0.5 Billion in options, with those numbers being mostly heavily weighted toward the first half of the year. Moderna is still having ongoing discussions with many countries about whether additional vaccines will need to be added to address the fall moving into winter of &#39;22. I expect that when all is said and done, Moderna could wind up signing additional APAs over the course of the year. So, it looks like 2022 might again be another banner year for Moderna.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e1246421e026d6fd58bec48546a19260\" tg-width=\"640\" tg-height=\"362\" width=\"100%\" height=\"auto\"/><span>How COVID-19 is likely to evolve</span></p><p>Currently, the world is in the midst of variant reinfection waves, which will likely continue throughout 2022 but by 2023 COVID-19 should become more seasonal and endemic. Morbidity waves are expected to become lower and lower over the next several years and there is a good chance that COVID-19 will be seen more like the flu is perceived today within a year or two. Post-pandemic, COVID-19 is expected to mostly only affect people aged 50-plus, health care workers, immunocompromised people and other high-risk populations. These groups will likely need boosters to ensure that they do not get severe disease and hospitalization. As COVID-19 winds down, demand for Spikevax will probably begin dropping in the 2023-to-2024-time frame. This is why some people have been predicting revenue declines for Moderna. Well, what is Moderna&#39;s post pandemic plan to replace the likely COVID-19 vaccine declining revenues?</p><p><b>Moderna&#39;s Plan Moving Forward</b></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a9965c1224ac3e57e5a4c764bbb50975\" tg-width=\"640\" tg-height=\"360\" width=\"100%\" height=\"auto\"/><span>Moderna Product Strategy in 2022</span></p><p>The initial way that Moderna plans on countering the likely COVID-19 vaccine decline is by bundling different seasonal respiratory vaccines together into just one vaccine. The days of getting COVID-19 specific vaccine seem to be waning and a pan-respiratory vaccine will likely compete extremely effectively with any laggards coming to the market late with only a COVID-19 solution.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4995949c9a253ebe6663e2deeb5ccce3\" tg-width=\"640\" tg-height=\"360\" width=\"100%\" height=\"auto\"/><span>Moderna vision for pan-respiratory vaccine</span></p><p>Moderna&#39;s vision is that an annual single-dose pan-respiratory booster can be customized to fit different demographics, different geographies, and different respiratory diseases over time. Eventually, Moderna even expects to target specific strains of respiratory diseases in specific regions. I wouldn&#39;t be surprised if a pan-respiratory vaccine starts to appear within two years.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eb027ec45a0750fdcd8b65307c4008d1\" tg-width=\"640\" tg-height=\"359\" width=\"100%\" height=\"auto\"/><span>Moderna Strategy After COVID-19</span></p><p>Unlike vaccine technology from companies like Novavax (NASDAQ:NVAX), mRNA can be used for many other different purposes besides infectious diseases.Novavax&#39;s pipeline only consists of 9 programs that target 5 other infectious diseases other than COVID-19. Most of Novavax&#39;s pipeline is mostly concerned with respiratory diseases, with only one direct contact latent virus, Ebola, appearing on the list.</p><p>In contrast, Moderna is much further ahead in developing solutions against multiple latent viruses that are a lot more prevalent than Ebola. The first ones being targeted and are already in clinical trials are CMV and EBV, with HIV soon to begin trials. CMV is Moderna&#39;s most advanced drug in the pipeline and the first patient has already been dosed in phase III trials. Besides CMV, EBV, and HIV, there a many other undisclosed latent viruses being worked on in the labs.</p><p>The next area that Moderna is prioritizing is in developing therapeutics using mRNA technology which allows the company to produce oncology products, cardio products, rare genetic disease products and autoimmune disease products. This is an area that has significant upside for Moderna. Moderna will be using totally new approaches to develop solutions against cancer and develop solutions for diseases that currently have no significant solutions. Recently, Moderna formed a partnership with Carisma Therapeutics. Moderna plans to combine its mRNA technology with Carisma Therapeutics&#39; engineered macrophage technology to develop solutions against solid tumor cancer. The reason why this is important is because while autologous CAR-Ts have really good data in Heme malignancies, which are blood cancers, they have not been very effective in solid tumors and eighty percent of cancer patients die of solid tumors. I won&#39;t go deep into the science behind it but scientist know the reasons why CAR-Ts are not as effective with solid tumors, and both companies think Carisma Therapeutics&#39; CAR-Macrophage&#39;s technology combined with mRNA technology can produce revolutionary new ways to essentially cure the most prevalent and difficult to treat form of cancer deaths which are solid tumors.</p><blockquote>Moderna&#39;s deep expertise in mRNA and LNP technologies opens up a potentially game-changing opportunity for engineered macrophages. In vivo delivery directly to monocytes and macrophages enables an off-the-shelf therapeutic approach that uses the patients&#39; own cells to provide a truly personalized treatment.</blockquote><blockquote>Source: Steven Kelly, President and Chief Executive Officer of Carisma</blockquote><p>Right now, there is no way to factor in the upside of Moderna potentially developing a significantly better solution to attacking and possibly curing solid tumor cancer. The therapies that could come out of partnerships like the one Moderna has with Carisma could potentially produce home runs just as big, if not bigger than the COVID-19 vaccine.</p><p>The fourth area that Moderna is developing solutions using gene-editing enzymes. Moderna has only seriously got into gene editing relatively recently when the company signed a collaboration with Metagenomi. For those unaware,gene-editing is the same strategy that companies like Editas (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are pursuing. The focus for the Metagenomi collaboration will be on serious genetic diseases.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8041f6f8edad22795cbe4a3295d68973\" tg-width=\"640\" tg-height=\"361\" width=\"100%\" height=\"auto\"/><span>Moderna capital allocation priorities</span></p><p>Moderna has already started spending its huge cash flows derived from COVID-19 vaccine sales. I just wanted to include the above slide in this article because it shows that Moderna&#39;s number one capital allocation priority is investing in R&amp;D, manufacturing infrastructure and continuing to build out the company&#39;s commercial infrastructure. The second priority is investing in external investment opportunities, either in the form of collaborations or M&amp;A. The collaborations with Metagenomi and Carisma Therapeutics are examples of this second priority.</p><p><b>Manufacturing Capacity</b></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/36484ebc09cffbacbfa8ce06eea49f22\" tg-width=\"640\" tg-height=\"357\" width=\"100%\" height=\"auto\"/><span>Moderna In-country vaccine manufacturing</span></p><p>There is a rather large set of existing potential competitors to Moderna and there are also countries like India that are supporting rising home-grown mRNA platform companies. One of the ways that Moderna is keeping ahead of such efforts from competitors is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow at the end of Q3, to build out significant mRNA manufacturing capability across the world. Moderna has announced in principle agreements with Australia and Canadato build out mRNA vaccine manufacturing plants within those countries. These announcements are in addition to the plans to build a factory capable of producing up to 500 million vaccine doses in Africa each year. I believe Moderna is still in the process of choosing which African country the manufacturing site will be located in.</p><p><b>Risks</b></p><p>The major risk that Moderna faces in the short term is revenue from the COVID-19 declining faster than Moderna can get other vaccines or therapies on to market and show superior results. The closest drug to approval is a CMV vaccine. An approval of the CMV vaccine would likely shoot Moderna&#39;s stock higher because it would show that mRNA is viable for addressing other diseases. A CMV rejection would likely drop Moderna&#39;s stock much lower.</p><p>Another major risk for Moderna are patent disputes and lawsuits. Moderna recently had to back down in a dispute with the NIH over COVID-19 patents and Moderna could also soon face a patent infringement lawsuit from Arbutus (NASDAQ:ABUS) over the COVID-19 vaccine. Currently, it is unknown how these disputes will impact Moderna over the longer term.</p><p><b>Analyst Price Targets</b></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0c0e5d79d00e415b16e4141b35eaaad4\" tg-width=\"461\" tg-height=\"416\" width=\"100%\" height=\"auto\"/><span>Moderna Analyst Price Targets</span></p><p>The above is based on 15 Wall Street analysts offering 12-month price targets for Moderna in the last 3 months. The average price target is $289.07 with a high forecast of $506.00 and a low forecast of $86.00. The average price target represents a 38% increase from the last price of $210.17.</p><p><b>Valuation</b></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/19ae061dd4c060bb37f43ff041dc2577\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4ff983411a9b9571f66378eddc98653c\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/259a902789541a798fdf388cf46d6b37\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p>The comparisons between these three relatively new biotechs with COVID-19 vaccines already shipping, shows Moderna is the most highly valued stock but BioNTech has the best revenue growth and operating margins. Going strictly by value, BioNTech is probably the best buy but in reality, all three companies are biotechs, in which one hit product or one large dismal failure can change the fortunes of the company. I view all three companies as very speculative, even with the success achieved by producing solutions for the COVID-19 pandemic.</p><p>I am not a big fan of trying to use valuation techniques on any biotech company. There is simply no way to value the future potential success or failure of the bets that many biotech companies make. If Moderna is part of curing solid tumor cancer, for instance, Moderna&#39;s current valuation will be viewed in hindsight as being way too low. If most of Moderna&#39;s pipeline fails then the valuation will be viewed in hindsight as being way too high.</p><p><b>Conclusion</b></p><p>Moderna is a high risk, high reward bet on mRNA technology succeeding in either preventing or curing many difficult to treat diseases. This is a stock that is strictly for long-term aggressive growth investors that are interested in speculating on potential home-run type products over a five-to-ten-year time frame. The risk that Moderna is only a one-product company is somewhat mitigated by the fact that the efficacy of the COVID-19 vaccine was so high, that is serves as a kind of proof of concept that a mRNA platform can produce other novel ways of addressing other difficult diseases.</p><p>The 58% pullback from Moderna&#39;s all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant potential upside. However, risk averse or investors sensitive to short-term price movements should avoid Moderna&#39;s stock for now because there is significant downside risk if COVID-19 revenue drops off too rapidly before Moderna can show that it can achieve similar success in addressing other diseases.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna: High Upside Potential At Current Prices</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna: High Upside Potential At Current Prices\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4479930-moderna-high-upside-potential-at-current-prices><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryModerna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company's mRNA manufacturing capacity.Moderna recently reported ...</p>\n\n<a href=\"https://seekingalpha.com/article/4479930-moderna-high-upside-potential-at-current-prices\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/article/4479930-moderna-high-upside-potential-at-current-prices","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131862461","content_text":"SummaryModerna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company's mRNA manufacturing capacity.Moderna recently reported the preliminary COVID-19 estimate for product sales in 2021 as being approximately $17.5 billion.Recently, Singapore released data showing that COVID-19 deaths were the lowest among Moderna vaccine takers.One of the ways that Moderna is keeping ahead of potential mRNA competition is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow to continue building out significant mRNA manufacturing capability across the world.The 58% pullback from Moderna's all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant upside potential.Maddie Meyer/Getty Images NewsModerna (NASDAQ:MRNA) has extremely high upside from being a first mover in developing the world's most advanced mRNA platform. One of the most promising potential solutions for helping prevent or cure some of the most intractable diseases known to man is mRNA technology and Moderna has not only developed the most advanced mRNA platform but has also built out significant mRNA manufacturing capacity worldwide. There are many companies that are in various stages of developing mRNA technology but there are very few that have advanced as far as Moderna has in both developing mRNA technology, as well as having the manufacturing capacity and other commercial infrastructure to produce billions of doses of a vaccine per year. At this time, the only companies that have both the knowledge of advanced mRNA techniques and the manufacturing capacity to compete in the same arena as Moderna is the BioNTech (NASDAQ:BNTX) - Pfizer (NYSE:PFE) partnership.Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company's mRNA manufacturing capacity. It is one thing to produce mRNA in a lab setting but quite another to safely mass produce effective vaccines in regulator approved manufacturing sites around the world. Moderna's first mover advantage has translated into a very large war chest of cash from COVID-19 sales in which the company can use to further its lead by investing in advancing mRNA technology, improving mRNA manufacturing processes, and building out significant manufacturing capability worldwide. Moderna is also well along in developing one of the deepest drug pipelines in the world.While a first mover advantage is not exactly a moat, for the next several years at least, Moderna should enjoy a significant lead in developing many different mRNA-based therapies or vaccines to treat numerous difficult to treat diseases. Moderna currently has 40 different drug development programs, which is almost unheard of for such a relatively young biotech company that only two years ago was simply a research outfit. In the end, Moderna's mRNA platform and manufacturing capacity should result in significant long-term upside for investors buying into Moderna's stock today.Advantages of mRNA TechnologyThe reason why Moderna was able to rapidly develop a COVID-19 solution, while at the same time continuing to build out a significant number of drug development programs is because of the nature of mRNA technology.The development and manufacturing of mRNA for use as therapeuticsandvaccines are comparatively simple, scalableandextremely rapid.Source:Millapore SigmaThere are numerous advantages of a mRNA platform over traditional drug making. The major advantages of a mRNA platform that were demonstrated by the response to the COVID-19 pandemic was the ability to take the sequence of the virus and quickly move from development, to clinical trials, to approval, to mass manufacturing of a vaccine in a very rapid period of time. As Moderna and others get more experience and regulatory bodies get more comfortable with mRNA technology, I can see the day in the future where the response time of discovery of a virulent virus to clinical trials of a vaccine, to vaccine approval, to mass manufacturing of the vaccine could significantly shrink. Right now, it looks like it takes about 9 months to a year to move from virus discovery to eventually making it into people's arms. Eventually, this response time could shrink to matter of a few months.Omnicron was first identified as a variant around November 24, 2021. Moderna CEO Stéphane Bancel said in a CNBC interview that clinical trials for an Omnicron vaccine will start soon and a Omnicron vaccine should be available by fall. This type of rapid response to infectious diseases is unheard of before now and as time goes along, mRNA platform companies could not only become proficient in rapidly producing vaccines against specific viruses but also become proficient at producing vaccines against specific strains of a virus, in specific regions of the world. Among the reason why I think Moderna is building manufacturing capacity in different countries and regions of the world is because vaccines will eventually be less of a one size fits all countries and be more along the lines of regional manufacturing sites creating vaccines specific for the most prevalent viruses and strains of virus in that specific region.Another potential huge advantage of a mRNA platform is flexibility. Theoretically, a mRNA manufacturing plant can be relatively rapidly switched to producing any other mRNA-based drug. It is possible that a mRNA plant that makes COVID-19 vaccines could be rapidly switched to making an Ebola vaccine, for instance. This is in contrast to the manufacturing process of many traditional drugs that require a dedicated plant to produce a drug. This could make the CapEx involved for producing multiple different types of drugs, far lower than a traditional drug manufacturer.The COVID-19 pandemic has highlighted exactly how easy it is to change the vaccine simply by plugging the genetic sequence of any virus that Moderna wants to target right into its basic mRNA platform. This is not only useful for being able to attack different strains of COVID-19 but also means that Moderna has the ability of using the sequence of any virus whether that be the flu, HIV, CMV, Tuberculosis, Zika, or Rabies and quickly produce a vaccine ready for testing.COVID-19 ProgressCOVID-19 has totally changed the fortunes of Moderna within just two years. Up until 2020, Moderna was only a little-known drug research outfit that had very little revenues but being the second company to bring a viable vaccine to protect against COVID-19 into US markets, has made Moderna very widely known worldwide and the company has built a huge brand that is on the verge of becoming a giant within the drug industry.There is real world evidence that up until now, Moderna has produced the most effective COVID-19 vaccine. Data from all over the world supports the very strong efficacy that was shown in phase III data in the USA. Recently, Singapore released data showing that COVID-19 deaths were lowest among Moderna takers. Singapore had 802 deaths out of which 70% were unvaccinated. Between Moderna, Pfizer-BioNTech, Sinopharm and Sinovac vaccines, Moderna had the least death rates:11 deaths per 100,000: Sinovac7.8 deaths per 100,000: Sinopharm6.2 deaths per 100,000: Pfizer/BioNTech1 death per 100,000: ModernaOver the course of 2021, Moderna shipped 807 million doses of Spikevax, Moderna's COVID-19 vaccine, to many different locations around the world, with around 25% of those doses going to low-income and middle-income countries. Moderna reported recently during the JPMorgan 40th Annual Healthcare Conference on January 10th, that the preliminary estimate for Spikevax product sales in 2021 is around $17.5 billion.Because of the huge demand for Moderna's vaccine worldwide, for a decent part of 2021, the company was supply constrained but that situation is beginning to turn around now. Moderna CEO Stephane Bancel attributes the reason for supply constraints as Moderna having a higher dose than the Pfizer-BioNTech vaccine. The higher dose was a big drain on manufacturing resources. Moderna has since built out additional manufacturing capacity over the course of 2021 and is now in much better shape to address COVID-19 demand. In Q4, Moderna shipped 300 million doses, which is a run rate of 1.2 billion doses. Moderna believes that they can produce two billion to three billion doses of boosters over the course of 2022, if necessary.Moderna Spikevax advanced purchase agreementsBecause COVID-19 vaccine makers have lately been having to play whack-a-mole with new variants, the demand for Spikevax is still rising. As can be seen from the above graphic, from November 4th to January 10th, Moderna has gained and additional $1.5 billion in advanced purchase agreements (\"APA\") and $0.5 Billion in options, with those numbers being mostly heavily weighted toward the first half of the year. Moderna is still having ongoing discussions with many countries about whether additional vaccines will need to be added to address the fall moving into winter of '22. I expect that when all is said and done, Moderna could wind up signing additional APAs over the course of the year. So, it looks like 2022 might again be another banner year for Moderna.How COVID-19 is likely to evolveCurrently, the world is in the midst of variant reinfection waves, which will likely continue throughout 2022 but by 2023 COVID-19 should become more seasonal and endemic. Morbidity waves are expected to become lower and lower over the next several years and there is a good chance that COVID-19 will be seen more like the flu is perceived today within a year or two. Post-pandemic, COVID-19 is expected to mostly only affect people aged 50-plus, health care workers, immunocompromised people and other high-risk populations. These groups will likely need boosters to ensure that they do not get severe disease and hospitalization. As COVID-19 winds down, demand for Spikevax will probably begin dropping in the 2023-to-2024-time frame. This is why some people have been predicting revenue declines for Moderna. Well, what is Moderna's post pandemic plan to replace the likely COVID-19 vaccine declining revenues?Moderna's Plan Moving ForwardModerna Product Strategy in 2022The initial way that Moderna plans on countering the likely COVID-19 vaccine decline is by bundling different seasonal respiratory vaccines together into just one vaccine. The days of getting COVID-19 specific vaccine seem to be waning and a pan-respiratory vaccine will likely compete extremely effectively with any laggards coming to the market late with only a COVID-19 solution.Moderna vision for pan-respiratory vaccineModerna's vision is that an annual single-dose pan-respiratory booster can be customized to fit different demographics, different geographies, and different respiratory diseases over time. Eventually, Moderna even expects to target specific strains of respiratory diseases in specific regions. I wouldn't be surprised if a pan-respiratory vaccine starts to appear within two years.Moderna Strategy After COVID-19Unlike vaccine technology from companies like Novavax (NASDAQ:NVAX), mRNA can be used for many other different purposes besides infectious diseases.Novavax's pipeline only consists of 9 programs that target 5 other infectious diseases other than COVID-19. Most of Novavax's pipeline is mostly concerned with respiratory diseases, with only one direct contact latent virus, Ebola, appearing on the list.In contrast, Moderna is much further ahead in developing solutions against multiple latent viruses that are a lot more prevalent than Ebola. The first ones being targeted and are already in clinical trials are CMV and EBV, with HIV soon to begin trials. CMV is Moderna's most advanced drug in the pipeline and the first patient has already been dosed in phase III trials. Besides CMV, EBV, and HIV, there a many other undisclosed latent viruses being worked on in the labs.The next area that Moderna is prioritizing is in developing therapeutics using mRNA technology which allows the company to produce oncology products, cardio products, rare genetic disease products and autoimmune disease products. This is an area that has significant upside for Moderna. Moderna will be using totally new approaches to develop solutions against cancer and develop solutions for diseases that currently have no significant solutions. Recently, Moderna formed a partnership with Carisma Therapeutics. Moderna plans to combine its mRNA technology with Carisma Therapeutics' engineered macrophage technology to develop solutions against solid tumor cancer. The reason why this is important is because while autologous CAR-Ts have really good data in Heme malignancies, which are blood cancers, they have not been very effective in solid tumors and eighty percent of cancer patients die of solid tumors. I won't go deep into the science behind it but scientist know the reasons why CAR-Ts are not as effective with solid tumors, and both companies think Carisma Therapeutics' CAR-Macrophage's technology combined with mRNA technology can produce revolutionary new ways to essentially cure the most prevalent and difficult to treat form of cancer deaths which are solid tumors.Moderna's deep expertise in mRNA and LNP technologies opens up a potentially game-changing opportunity for engineered macrophages. In vivo delivery directly to monocytes and macrophages enables an off-the-shelf therapeutic approach that uses the patients' own cells to provide a truly personalized treatment.Source: Steven Kelly, President and Chief Executive Officer of CarismaRight now, there is no way to factor in the upside of Moderna potentially developing a significantly better solution to attacking and possibly curing solid tumor cancer. The therapies that could come out of partnerships like the one Moderna has with Carisma could potentially produce home runs just as big, if not bigger than the COVID-19 vaccine.The fourth area that Moderna is developing solutions using gene-editing enzymes. Moderna has only seriously got into gene editing relatively recently when the company signed a collaboration with Metagenomi. For those unaware,gene-editing is the same strategy that companies like Editas (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are pursuing. The focus for the Metagenomi collaboration will be on serious genetic diseases.Moderna capital allocation prioritiesModerna has already started spending its huge cash flows derived from COVID-19 vaccine sales. I just wanted to include the above slide in this article because it shows that Moderna's number one capital allocation priority is investing in R&D, manufacturing infrastructure and continuing to build out the company's commercial infrastructure. The second priority is investing in external investment opportunities, either in the form of collaborations or M&A. The collaborations with Metagenomi and Carisma Therapeutics are examples of this second priority.Manufacturing CapacityModerna In-country vaccine manufacturingThere is a rather large set of existing potential competitors to Moderna and there are also countries like India that are supporting rising home-grown mRNA platform companies. One of the ways that Moderna is keeping ahead of such efforts from competitors is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow at the end of Q3, to build out significant mRNA manufacturing capability across the world. Moderna has announced in principle agreements with Australia and Canadato build out mRNA vaccine manufacturing plants within those countries. These announcements are in addition to the plans to build a factory capable of producing up to 500 million vaccine doses in Africa each year. I believe Moderna is still in the process of choosing which African country the manufacturing site will be located in.RisksThe major risk that Moderna faces in the short term is revenue from the COVID-19 declining faster than Moderna can get other vaccines or therapies on to market and show superior results. The closest drug to approval is a CMV vaccine. An approval of the CMV vaccine would likely shoot Moderna's stock higher because it would show that mRNA is viable for addressing other diseases. A CMV rejection would likely drop Moderna's stock much lower.Another major risk for Moderna are patent disputes and lawsuits. Moderna recently had to back down in a dispute with the NIH over COVID-19 patents and Moderna could also soon face a patent infringement lawsuit from Arbutus (NASDAQ:ABUS) over the COVID-19 vaccine. Currently, it is unknown how these disputes will impact Moderna over the longer term.Analyst Price TargetsModerna Analyst Price TargetsThe above is based on 15 Wall Street analysts offering 12-month price targets for Moderna in the last 3 months. The average price target is $289.07 with a high forecast of $506.00 and a low forecast of $86.00. The average price target represents a 38% increase from the last price of $210.17.ValuationData by YChartsData by YChartsData by YChartsThe comparisons between these three relatively new biotechs with COVID-19 vaccines already shipping, shows Moderna is the most highly valued stock but BioNTech has the best revenue growth and operating margins. Going strictly by value, BioNTech is probably the best buy but in reality, all three companies are biotechs, in which one hit product or one large dismal failure can change the fortunes of the company. I view all three companies as very speculative, even with the success achieved by producing solutions for the COVID-19 pandemic.I am not a big fan of trying to use valuation techniques on any biotech company. There is simply no way to value the future potential success or failure of the bets that many biotech companies make. If Moderna is part of curing solid tumor cancer, for instance, Moderna's current valuation will be viewed in hindsight as being way too low. If most of Moderna's pipeline fails then the valuation will be viewed in hindsight as being way too high.ConclusionModerna is a high risk, high reward bet on mRNA technology succeeding in either preventing or curing many difficult to treat diseases. This is a stock that is strictly for long-term aggressive growth investors that are interested in speculating on potential home-run type products over a five-to-ten-year time frame. The risk that Moderna is only a one-product company is somewhat mitigated by the fact that the efficacy of the COVID-19 vaccine was so high, that is serves as a kind of proof of concept that a mRNA platform can produce other novel ways of addressing other difficult diseases.The 58% pullback from Moderna's all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant potential upside. However, risk averse or investors sensitive to short-term price movements should avoid Moderna's stock for now because there is significant downside risk if COVID-19 revenue drops off too rapidly before Moderna can show that it can achieve similar success in addressing other diseases.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9005268090,"gmtCreate":1642314363713,"gmtModify":1676533700692,"author":{"id":"4100154790997510","authorId":"4100154790997510","name":"eslebe","avatar":"https://static.tigerbbs.com/49b59eaa11d91f8e50747a353d6075a7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100154790997510","authorIdStr":"4100154790997510"},"themes":[],"htmlText":"Disappointed with the disappointing results!","listText":"Disappointed with the disappointing results!","text":"Disappointed with the disappointing results!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005268090","repostId":"2203201745","repostType":4,"repost":{"id":"2203201745","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1642201908,"share":"https://ttm.financial/m/news/2203201745?lang=&edition=fundamental","pubTime":"2022-01-15 07:11","market":"us","language":"en","title":"US STOCKS-Dow Closes Lower after Disappointing Bank Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2203201745","media":"Reuters","summary":"The Dow closed lower with a big drag from financial stocks as investors were disappointed by fourth quarter results from big U.S. banks, which cast a shadow over the earnings season kick-off.The Nasda","content":"<html><head></head><body><p>The Dow closed lower with a big drag from financial stocks as investors were disappointed by fourth quarter results from big U.S. banks, which cast a shadow over the earnings season kick-off.</p><p>The Nasdaq and the S&amp;P regained lost ground in afternoon trading to close higher. Meanwhile the consumer discretionary</p><p>also put pressure on major indexes after morning data showed a December decline in retail sales and a souring of consumer sentiment.</p><p>JPMorgan Chase &amp; Co tumbled after reporting weaker performance at its trading arm. The bellwether lender also warned that soaring inflation, the looming threat of Omicron and trading revenues would challenge industry growth in coming months.</p><p>Along with JPMorgan, big decliners putting pressure on the Dow included Goldman Sachs, American Express and Home Depot.</p><p>$Citigroup Inc(C-N)$ shares fell after it reported a 26% drop in fourth-quarter profit, while asset manager BlackRock Inc</p><p>fell after missing quarterly revenue expectations.</p><p>The earnings kick-off had investors taking profits in the S&amp;P 500 bank subsector after it had hit an intraday high in the previous session. Financial stocks had been outperforming the S&amp;P recently as investors bet that the Federal Reserve&#39;s expected interest rate hikes will boost bank profits.</p><p>&#34;The bar was very high going into (JPMorgan) results. On the surface it was good but, under the hood, not so much,&#34; said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles. In the interest rate hiking cycle expected this year &#34;positioning was very crowded on the long side&#34; going into the earnings season.</p><p>For consumer stock weakness, James pointed to &#34;clearly disappointing&#34; retail sales, which dropped 1.9% last month due to shortages of goods and an explosion of COVID-19 infections.</p><p>Separate data showed soaring inflation hit U.S. consumer sentiment in January, pushing it to its second lowest level in a decade.</p><p>Retail sales and bank loan growth raised doubts about the economic outlook for the current quarter and 2022 for Keith Buchanan, portfolio manager at Globalt in Atlanta.</p><p>&#34;The question is, does the economy have enough strength to get through the risk Omicron brings as fiscal and monetary stimulus is rolling off,&#34; Buchanan said.</p><p>According to preliminary data, the S&amp;P 500 gained 2.89 points, or 0.06%, to end at 4,661.92 points, while the Nasdaq Composite gained 81.98 points, or 0.55%, to 14,889.73. The Dow Jones Industrial Average fell 208.43 points, or 0.58%, to 35,905.19.</p><p>Analysts see S&amp;P 500 companies earnings rising 23.1% in the fourth quarter, according to IBES data from Refinitiv.</p><p>One bright spot in the bank sector on Friday however was Wells Fargo &amp; Co, which gained ground after posting a bigger-than-expected rise in fourth-quarter profit.</p><p>Casino operators Las Vegas Sands, Melco Resorts and Wynn Resorts rallied after Macau&#39;s government capped the number of new casino operators allowed to operate to six for a period of 10 years.</p><p>U.S. stock markets will remain shut on Monday for the public holiday in honor of Martin Luther King.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US STOCKS-Dow Closes Lower after Disappointing Bank Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS STOCKS-Dow Closes Lower after Disappointing Bank Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-01-15 07:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>The Dow closed lower with a big drag from financial stocks as investors were disappointed by fourth quarter results from big U.S. banks, which cast a shadow over the earnings season kick-off.</p><p>The Nasdaq and the S&amp;P regained lost ground in afternoon trading to close higher. Meanwhile the consumer discretionary</p><p>also put pressure on major indexes after morning data showed a December decline in retail sales and a souring of consumer sentiment.</p><p>JPMorgan Chase &amp; Co tumbled after reporting weaker performance at its trading arm. The bellwether lender also warned that soaring inflation, the looming threat of Omicron and trading revenues would challenge industry growth in coming months.</p><p>Along with JPMorgan, big decliners putting pressure on the Dow included Goldman Sachs, American Express and Home Depot.</p><p>$Citigroup Inc(C-N)$ shares fell after it reported a 26% drop in fourth-quarter profit, while asset manager BlackRock Inc</p><p>fell after missing quarterly revenue expectations.</p><p>The earnings kick-off had investors taking profits in the S&amp;P 500 bank subsector after it had hit an intraday high in the previous session. Financial stocks had been outperforming the S&amp;P recently as investors bet that the Federal Reserve&#39;s expected interest rate hikes will boost bank profits.</p><p>&#34;The bar was very high going into (JPMorgan) results. On the surface it was good but, under the hood, not so much,&#34; said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles. In the interest rate hiking cycle expected this year &#34;positioning was very crowded on the long side&#34; going into the earnings season.</p><p>For consumer stock weakness, James pointed to &#34;clearly disappointing&#34; retail sales, which dropped 1.9% last month due to shortages of goods and an explosion of COVID-19 infections.</p><p>Separate data showed soaring inflation hit U.S. consumer sentiment in January, pushing it to its second lowest level in a decade.</p><p>Retail sales and bank loan growth raised doubts about the economic outlook for the current quarter and 2022 for Keith Buchanan, portfolio manager at Globalt in Atlanta.</p><p>&#34;The question is, does the economy have enough strength to get through the risk Omicron brings as fiscal and monetary stimulus is rolling off,&#34; Buchanan said.</p><p>According to preliminary data, the S&amp;P 500 gained 2.89 points, or 0.06%, to end at 4,661.92 points, while the Nasdaq Composite gained 81.98 points, or 0.55%, to 14,889.73. The Dow Jones Industrial Average fell 208.43 points, or 0.58%, to 35,905.19.</p><p>Analysts see S&amp;P 500 companies earnings rising 23.1% in the fourth quarter, according to IBES data from Refinitiv.</p><p>One bright spot in the bank sector on Friday however was Wells Fargo &amp; Co, which gained ground after posting a bigger-than-expected rise in fourth-quarter profit.</p><p>Casino operators Las Vegas Sands, Melco Resorts and Wynn Resorts rallied after Macau&#39;s government capped the number of new casino operators allowed to operate to six for a period of 10 years.</p><p>U.S. stock markets will remain shut on Monday for the public holiday in honor of Martin Luther King.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)",".SPX":"S&P 500 Index","BK4559":"巴菲特持仓","AXP":"美国运通","BK4504":"桥水持仓","BK4166":"消费信贷",".DJI":"道琼斯","SPY":"标普500ETF","BK4566":"资本集团","GS":"高盛","BK4083":"家庭装潢零售","BK4550":"红杉资本持仓","BK4567":"ESG概念","HD":"家得宝","BK4534":"瑞士信贷持仓",".IXIC":"NASDAQ Composite"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2203201745","content_text":"The Dow closed lower with a big drag from financial stocks as investors were disappointed by fourth quarter results from big U.S. banks, which cast a shadow over the earnings season kick-off.The Nasdaq and the S&P regained lost ground in afternoon trading to close higher. Meanwhile the consumer discretionaryalso put pressure on major indexes after morning data showed a December decline in retail sales and a souring of consumer sentiment.JPMorgan Chase & Co tumbled after reporting weaker performance at its trading arm. The bellwether lender also warned that soaring inflation, the looming threat of Omicron and trading revenues would challenge industry growth in coming months.Along with JPMorgan, big decliners putting pressure on the Dow included Goldman Sachs, American Express and Home Depot.$Citigroup Inc(C-N)$ shares fell after it reported a 26% drop in fourth-quarter profit, while asset manager BlackRock Incfell after missing quarterly revenue expectations.The earnings kick-off had investors taking profits in the S&P 500 bank subsector after it had hit an intraday high in the previous session. Financial stocks had been outperforming the S&P recently as investors bet that the Federal Reserve's expected interest rate hikes will boost bank profits.\"The bar was very high going into (JPMorgan) results. On the surface it was good but, under the hood, not so much,\" said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles. In the interest rate hiking cycle expected this year \"positioning was very crowded on the long side\" going into the earnings season.For consumer stock weakness, James pointed to \"clearly disappointing\" retail sales, which dropped 1.9% last month due to shortages of goods and an explosion of COVID-19 infections.Separate data showed soaring inflation hit U.S. consumer sentiment in January, pushing it to its second lowest level in a decade.Retail sales and bank loan growth raised doubts about the economic outlook for the current quarter and 2022 for Keith Buchanan, portfolio manager at Globalt in Atlanta.\"The question is, does the economy have enough strength to get through the risk Omicron brings as fiscal and monetary stimulus is rolling off,\" Buchanan said.According to preliminary data, the S&P 500 gained 2.89 points, or 0.06%, to end at 4,661.92 points, while the Nasdaq Composite gained 81.98 points, or 0.55%, to 14,889.73. The Dow Jones Industrial Average fell 208.43 points, or 0.58%, to 35,905.19.Analysts see S&P 500 companies earnings rising 23.1% in the fourth quarter, according to IBES data from Refinitiv.One bright spot in the bank sector on Friday however was Wells Fargo & Co, which gained ground after posting a bigger-than-expected rise in fourth-quarter profit.Casino operators Las Vegas Sands, Melco Resorts and Wynn Resorts rallied after Macau's government capped the number of new casino operators allowed to operate to six for a period of 10 years.U.S. stock markets will remain shut on Monday for the public holiday in honor of Martin Luther King.","news_type":1,"symbols_score_info":{".DJI":0.9,"SPY":0.6,".IXIC":0.9,".SPX":0.9,"AXP":0.9,"GS":0.9,"HD":0.9}},"isVote":1,"tweetType":1,"viewCount":2160,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9005048353,"gmtCreate":1642126052839,"gmtModify":1676533684372,"author":{"id":"4100154790997510","authorId":"4100154790997510","name":"eslebe","avatar":"https://static.tigerbbs.com/49b59eaa11d91f8e50747a353d6075a7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100154790997510","authorIdStr":"4100154790997510"},"themes":[],"htmlText":"Lai liao... lai liao...","listText":"Lai liao... lai liao...","text":"Lai liao... lai liao...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005048353","repostId":"1181330831","repostType":4,"isVote":1,"tweetType":1,"viewCount":2627,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9005041260,"gmtCreate":1642125989965,"gmtModify":1676533684356,"author":{"id":"4100154790997510","authorId":"4100154790997510","name":"eslebe","avatar":"https://static.tigerbbs.com/49b59eaa11d91f8e50747a353d6075a7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100154790997510","authorIdStr":"4100154790997510"},"themes":[],"htmlText":"What happened siah???","listText":"What happened siah???","text":"What happened siah???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005041260","repostId":"2203796901","repostType":4,"isVote":1,"tweetType":1,"viewCount":2238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002184209,"gmtCreate":1641946528609,"gmtModify":1676533664612,"author":{"id":"4100154790997510","authorId":"4100154790997510","name":"eslebe","avatar":"https://static.tigerbbs.com/49b59eaa11d91f8e50747a353d6075a7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100154790997510","authorIdStr":"4100154790997510"},"themes":[],"htmlText":"Powell is power!!!&nbsp;[Like]&nbsp;","listText":"Powell is power!!!&nbsp;[Like]&nbsp;","text":"Powell is power!!! [Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002184209","repostId":"2202787736","repostType":4,"isVote":1,"tweetType":1,"viewCount":2254,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002972947,"gmtCreate":1641906666243,"gmtModify":1676533660433,"author":{"id":"4100154790997510","authorId":"4100154790997510","name":"eslebe","avatar":"https://static.tigerbbs.com/49b59eaa11d91f8e50747a353d6075a7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100154790997510","authorIdStr":"4100154790997510"},"themes":[],"htmlText":"Green or Red day???","listText":"Green or Red day???","text":"Green or Red day???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002972947","repostId":"1134633803","repostType":4,"repost":{"id":"1134633803","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641906072,"share":"https://ttm.financial/m/news/1134633803?lang=&edition=fundamental","pubTime":"2022-01-11 21:01","market":"us","language":"en","title":"Toplines Before US Market Open on Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1134633803","media":"Tiger Newspress","summary":"U.S. stock index futures rose on Tuesday as investors picked up beaten-down stocks ahead of Federal ","content":"<html><head></head><body><p>U.S. stock index futures rose on Tuesday as investors picked up beaten-down stocks ahead of Federal Reserve Chair Jerome Powell&#39;s testimony that may offer fresh insight on policy tightening and the central bank&#39;s plans to tackle inflation.</p><p>At 8:00 a.m. ET, Dow E-minis were up 27 points, or 0.08%, S&amp;P 500 E-minis were up 7.5 points, or 0.16% and Nasdaq 100 E-minis were up 37.75 points, or 0.24%.</p><p><img src=\"https://static.tigerbbs.com/d7cb941cce9f5cb9aa1d279dac347aad\" tg-width=\"1080\" tg-height=\"370\" width=\"100%\" height=\"auto\"/></p><p>Megacap growth companies including <a href=\"https://laohu8.com/S/AAPL\">Apple Inc</a>, Amazon.com Inc , <a href=\"https://laohu8.com/S/MSFT\">Microsoft Corp</a>, <a href=\"https://laohu8.com/S/FB\">Meta Platforms Inc</a> and <a href=\"https://laohu8.com/S/TSLA\">Tesla Inc</a> rose up to 1% in premarket trading.</p><p>Marko Kolanovic, chief global markets strategist at JPMorgan Chase &amp; Co, called the recent pull-back in riskier assets &#34;arguably overdone&#34; and said it presented investors with a buying opportunity.</p><p>Powell is set to appear before the Senate Banking Committee at 10 a.m ET for consideration for a second four-year term as head of the Fed, while Lael Brainard is set to appear before the same panel on Thursday for promotion to a four-year term as Fed vice chair.</p><p><b>Stocks making the biggest moves in the premarket:</b></p><p><a href=\"https://laohu8.com/S/ILMN\">Illumina </a> – Illumina issued a 2022 revenue outlook that exceeded consensus analysts’ estimates, noting strong demand for its gene sequencing treatments as well as new partnerships with four health care companies. Illumina jumped 4.1% in the premarket.</p><p><a href=\"https://laohu8.com/S/RIVN\">Rivian</a> – Rivian fell 3.5% in premarket trading following news that its Chief Operating Officer Rod Copes had left the electric truck maker.</p><p><a href=\"https://laohu8.com/S/JNPR\">Juniper Networks</a> – Juniper shares rallied 5.3% in the premarket following a double upgrade by BofA Securities to “buy” from “underperform.” The firm said that most networking vendors are still attractively valued and said Juniper’s current guidance from management appears conservative.</p><p><a href=\"https://laohu8.com/S/ACI\">Albertsons</a> – The supermarket operator reported quarterly earnings of 74 cents per share, 14 cents a share above estimates. Revenue also topped Wall Street forecasts. Albertsons shares jumped 3.5% in premarket trading.</p><p><a href=\"https://laohu8.com/S/INTC\">Intel</a> – Intel namedMicron Technology(MU) Chief Financial Officer David Zinsner as its new CFO, effective next Monday. At the same time, the chipmaker announced the departure of client computing group head Gregory Bryant at the end of January. Intel rose 1.7% in the premarket, while Micron was down 1%.</p><p><a href=\"https://laohu8.com/S/ACCD\">Accolade</a> – The workplace benefits technology company surged 10.9% in premarket action, following better-than-expected quarterly results. Accolade earned 31 cents per share, compared to analysts’ forecasts of a 74 cents per share loss. The company also issued an improved full-year revenue outlook.</p><p><a href=\"https://laohu8.com/S/IBM\">IBM</a> – IBM shares fell 2.3% in the premarket after UBS downgraded it to “sell” from “neutral,” citing risks to operating results as well as what it feels is an “elevated valuation.”</p><p><a href=\"https://laohu8.com/S/CVS\">CVS Health</a> – The drug store operator and pharmacy benefits manager raised its full-year earnings outlook, now expecting a profit of $8.33 to $8.38 per share. That compares to a prior outlook of “at least” $8.00 per share and a current consensus estimate of $8.03 per share. CVS rose 1.1% in the premarket.</p><p><a href=\"https://laohu8.com/S/BIG\">Big Lots</a> – Big Lots said it has seen a softening of traffic and sales trends this month, with the discount retailer citing winter weather and the spread of the Covid-19 omicron variant. Shares tumbled 7.4% in premarket trading.</p><p><a href=\"https://laohu8.com/S/ANF\">Abercrombie &amp; Fitch</a> – Abercrombie rallied 5.9% in the premarket, despite a cut in the apparel retailer’s quarterly sales outlook. While issuing that outlook, Abercrombie also said it had seen a pickup in post-holiday sales.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-11 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>U.S. stock index futures rose on Tuesday as investors picked up beaten-down stocks ahead of Federal Reserve Chair Jerome Powell&#39;s testimony that may offer fresh insight on policy tightening and the central bank&#39;s plans to tackle inflation.</p><p>At 8:00 a.m. ET, Dow E-minis were up 27 points, or 0.08%, S&amp;P 500 E-minis were up 7.5 points, or 0.16% and Nasdaq 100 E-minis were up 37.75 points, or 0.24%.</p><p><img src=\"https://static.tigerbbs.com/d7cb941cce9f5cb9aa1d279dac347aad\" tg-width=\"1080\" tg-height=\"370\" width=\"100%\" height=\"auto\"/></p><p>Megacap growth companies including <a href=\"https://laohu8.com/S/AAPL\">Apple Inc</a>, Amazon.com Inc , <a href=\"https://laohu8.com/S/MSFT\">Microsoft Corp</a>, <a href=\"https://laohu8.com/S/FB\">Meta Platforms Inc</a> and <a href=\"https://laohu8.com/S/TSLA\">Tesla Inc</a> rose up to 1% in premarket trading.</p><p>Marko Kolanovic, chief global markets strategist at JPMorgan Chase &amp; Co, called the recent pull-back in riskier assets &#34;arguably overdone&#34; and said it presented investors with a buying opportunity.</p><p>Powell is set to appear before the Senate Banking Committee at 10 a.m ET for consideration for a second four-year term as head of the Fed, while Lael Brainard is set to appear before the same panel on Thursday for promotion to a four-year term as Fed vice chair.</p><p><b>Stocks making the biggest moves in the premarket:</b></p><p><a href=\"https://laohu8.com/S/ILMN\">Illumina </a> – Illumina issued a 2022 revenue outlook that exceeded consensus analysts’ estimates, noting strong demand for its gene sequencing treatments as well as new partnerships with four health care companies. Illumina jumped 4.1% in the premarket.</p><p><a href=\"https://laohu8.com/S/RIVN\">Rivian</a> – Rivian fell 3.5% in premarket trading following news that its Chief Operating Officer Rod Copes had left the electric truck maker.</p><p><a href=\"https://laohu8.com/S/JNPR\">Juniper Networks</a> – Juniper shares rallied 5.3% in the premarket following a double upgrade by BofA Securities to “buy” from “underperform.” The firm said that most networking vendors are still attractively valued and said Juniper’s current guidance from management appears conservative.</p><p><a href=\"https://laohu8.com/S/ACI\">Albertsons</a> – The supermarket operator reported quarterly earnings of 74 cents per share, 14 cents a share above estimates. Revenue also topped Wall Street forecasts. Albertsons shares jumped 3.5% in premarket trading.</p><p><a href=\"https://laohu8.com/S/INTC\">Intel</a> – Intel namedMicron Technology(MU) Chief Financial Officer David Zinsner as its new CFO, effective next Monday. At the same time, the chipmaker announced the departure of client computing group head Gregory Bryant at the end of January. Intel rose 1.7% in the premarket, while Micron was down 1%.</p><p><a href=\"https://laohu8.com/S/ACCD\">Accolade</a> – The workplace benefits technology company surged 10.9% in premarket action, following better-than-expected quarterly results. Accolade earned 31 cents per share, compared to analysts’ forecasts of a 74 cents per share loss. The company also issued an improved full-year revenue outlook.</p><p><a href=\"https://laohu8.com/S/IBM\">IBM</a> – IBM shares fell 2.3% in the premarket after UBS downgraded it to “sell” from “neutral,” citing risks to operating results as well as what it feels is an “elevated valuation.”</p><p><a href=\"https://laohu8.com/S/CVS\">CVS Health</a> – The drug store operator and pharmacy benefits manager raised its full-year earnings outlook, now expecting a profit of $8.33 to $8.38 per share. That compares to a prior outlook of “at least” $8.00 per share and a current consensus estimate of $8.03 per share. CVS rose 1.1% in the premarket.</p><p><a href=\"https://laohu8.com/S/BIG\">Big Lots</a> – Big Lots said it has seen a softening of traffic and sales trends this month, with the discount retailer citing winter weather and the spread of the Covid-19 omicron variant. Shares tumbled 7.4% in premarket trading.</p><p><a href=\"https://laohu8.com/S/ANF\">Abercrombie &amp; Fitch</a> – Abercrombie rallied 5.9% in the premarket, despite a cut in the apparel retailer’s quarterly sales outlook. While issuing that outlook, Abercrombie also said it had seen a pickup in post-holiday sales.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134633803","content_text":"U.S. stock index futures rose on Tuesday as investors picked up beaten-down stocks ahead of Federal Reserve Chair Jerome Powell's testimony that may offer fresh insight on policy tightening and the central bank's plans to tackle inflation.At 8:00 a.m. ET, Dow E-minis were up 27 points, or 0.08%, S&P 500 E-minis were up 7.5 points, or 0.16% and Nasdaq 100 E-minis were up 37.75 points, or 0.24%.Megacap growth companies including Apple Inc, Amazon.com Inc , Microsoft Corp, Meta Platforms Inc and Tesla Inc rose up to 1% in premarket trading.Marko Kolanovic, chief global markets strategist at JPMorgan Chase & Co, called the recent pull-back in riskier assets \"arguably overdone\" and said it presented investors with a buying opportunity.Powell is set to appear before the Senate Banking Committee at 10 a.m ET for consideration for a second four-year term as head of the Fed, while Lael Brainard is set to appear before the same panel on Thursday for promotion to a four-year term as Fed vice chair.Stocks making the biggest moves in the premarket:Illumina  – Illumina issued a 2022 revenue outlook that exceeded consensus analysts’ estimates, noting strong demand for its gene sequencing treatments as well as new partnerships with four health care companies. Illumina jumped 4.1% in the premarket.Rivian – Rivian fell 3.5% in premarket trading following news that its Chief Operating Officer Rod Copes had left the electric truck maker.Juniper Networks – Juniper shares rallied 5.3% in the premarket following a double upgrade by BofA Securities to “buy” from “underperform.” The firm said that most networking vendors are still attractively valued and said Juniper’s current guidance from management appears conservative.Albertsons – The supermarket operator reported quarterly earnings of 74 cents per share, 14 cents a share above estimates. Revenue also topped Wall Street forecasts. Albertsons shares jumped 3.5% in premarket trading.Intel – Intel namedMicron Technology(MU) Chief Financial Officer David Zinsner as its new CFO, effective next Monday. At the same time, the chipmaker announced the departure of client computing group head Gregory Bryant at the end of January. Intel rose 1.7% in the premarket, while Micron was down 1%.Accolade – The workplace benefits technology company surged 10.9% in premarket action, following better-than-expected quarterly results. Accolade earned 31 cents per share, compared to analysts’ forecasts of a 74 cents per share loss. The company also issued an improved full-year revenue outlook.IBM – IBM shares fell 2.3% in the premarket after UBS downgraded it to “sell” from “neutral,” citing risks to operating results as well as what it feels is an “elevated valuation.”CVS Health – The drug store operator and pharmacy benefits manager raised its full-year earnings outlook, now expecting a profit of $8.33 to $8.38 per share. That compares to a prior outlook of “at least” $8.00 per share and a current consensus estimate of $8.03 per share. CVS rose 1.1% in the premarket.Big Lots – Big Lots said it has seen a softening of traffic and sales trends this month, with the discount retailer citing winter weather and the spread of the Covid-19 omicron variant. Shares tumbled 7.4% in premarket trading.Abercrombie & Fitch – Abercrombie rallied 5.9% in the premarket, despite a cut in the apparel retailer’s quarterly sales outlook. While issuing that outlook, Abercrombie also said it had seen a pickup in post-holiday sales.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":2713,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006041572,"gmtCreate":1641564652621,"gmtModify":1676533629606,"author":{"id":"4100154790997510","authorId":"4100154790997510","name":"eslebe","avatar":"https://static.tigerbbs.com/49b59eaa11d91f8e50747a353d6075a7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100154790997510","authorIdStr":"4100154790997510"},"themes":[],"htmlText":"Doesn't look promising.","listText":"Doesn't look promising.","text":"Doesn't look promising.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006041572","repostId":"1198195110","repostType":4,"repost":{"id":"1198195110","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641562441,"share":"https://ttm.financial/m/news/1198195110?lang=&edition=fundamental","pubTime":"2022-01-07 21:34","market":"us","language":"en","title":"Hiring Falters in December as Payrolls Rise Only 199,000, though the Unemployment Fell to 3.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1198195110","media":"Tiger Newspress","summary":"The U.S. economy added far fewer jobs than expected in December just as the nation was grappling wit","content":"<html><head></head><body><p>The U.S. economy added far fewer jobs than expected in December just as the nation was grappling with a massive surge in Covid cases, the Labor Department said Friday.</p><p>Nonfarm payrolls grew by 199,000, while the unemployment rate fell to 3.9%, according to Bureau of Labor Statistics data. That compared to the Dow Jones estimate of 422,000 for the payrolls number and 4.1% for the unemployment rate.</p><p>Job creation was highest in leisure and hospitality, a key recovery sector, which added 53,000. Professional and business services contributed 43,000 while manufacturing added 43,000.</p><p>The numbers come at a crossroads for the U.S. economy as more than half a million Covid cases per day, many related to the omicron variant, threaten to stall an economic recovery that looks to accelerate in 2022.</p><p>While growth decelerated through the summer, economists expect that GDP rose sharply at the end of the year, with the Atlanta Fed tracking 6.7% growth. Federal Reserve officials have been watching the data closely.</p><p>Inflation is running at its strongest pace in nearly 40 years, while some policymakers see the jobs market near full employment. Consequently, the central bank has indicated it will begin slowing the help it has been providing the economy since the pandemic began.</p><p>Friday’s report covered the week including Dec. 12, which came before the worst of an omicron spike that began heading into Christmas.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hiring Falters in December as Payrolls Rise Only 199,000, though the Unemployment Fell to 3.9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHiring Falters in December as Payrolls Rise Only 199,000, though the Unemployment Fell to 3.9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-07 21:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>The U.S. economy added far fewer jobs than expected in December just as the nation was grappling with a massive surge in Covid cases, the Labor Department said Friday.</p><p>Nonfarm payrolls grew by 199,000, while the unemployment rate fell to 3.9%, according to Bureau of Labor Statistics data. That compared to the Dow Jones estimate of 422,000 for the payrolls number and 4.1% for the unemployment rate.</p><p>Job creation was highest in leisure and hospitality, a key recovery sector, which added 53,000. Professional and business services contributed 43,000 while manufacturing added 43,000.</p><p>The numbers come at a crossroads for the U.S. economy as more than half a million Covid cases per day, many related to the omicron variant, threaten to stall an economic recovery that looks to accelerate in 2022.</p><p>While growth decelerated through the summer, economists expect that GDP rose sharply at the end of the year, with the Atlanta Fed tracking 6.7% growth. Federal Reserve officials have been watching the data closely.</p><p>Inflation is running at its strongest pace in nearly 40 years, while some policymakers see the jobs market near full employment. Consequently, the central bank has indicated it will begin slowing the help it has been providing the economy since the pandemic began.</p><p>Friday’s report covered the week including Dec. 12, which came before the worst of an omicron spike that began heading into Christmas.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198195110","content_text":"The U.S. economy added far fewer jobs than expected in December just as the nation was grappling with a massive surge in Covid cases, the Labor Department said Friday.Nonfarm payrolls grew by 199,000, while the unemployment rate fell to 3.9%, according to Bureau of Labor Statistics data. That compared to the Dow Jones estimate of 422,000 for the payrolls number and 4.1% for the unemployment rate.Job creation was highest in leisure and hospitality, a key recovery sector, which added 53,000. Professional and business services contributed 43,000 while manufacturing added 43,000.The numbers come at a crossroads for the U.S. economy as more than half a million Covid cases per day, many related to the omicron variant, threaten to stall an economic recovery that looks to accelerate in 2022.While growth decelerated through the summer, economists expect that GDP rose sharply at the end of the year, with the Atlanta Fed tracking 6.7% growth. Federal Reserve officials have been watching the data closely.Inflation is running at its strongest pace in nearly 40 years, while some policymakers see the jobs market near full employment. Consequently, the central bank has indicated it will begin slowing the help it has been providing the economy since the pandemic began.Friday’s report covered the week including Dec. 12, which came before the worst of an omicron spike that began heading into Christmas.","news_type":1,"symbols_score_info":{".IXIC":0.9,".SPX":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":2851,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}